Doberauer C, Niederle N, Kloke O, Kurschel E, Schmidt C G
Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen.
Onkologie. 1987 Dec;10(6):340-4. doi: 10.1159/000216440.
Seven patients with progressive ileal or caecal carcinoid tumors and liver metastases were treated with human recombinant alpha-interferon (IFN alfa-2b) at a dosage of 2-4 x 10(6) U daily or every other day subcutaneously. Six patients had symptoms of the carcinoid syndrome. No change of tumor size lasting 4 to 40+ months (median, 18 months) was noted in 6 patients, and 1 patient had hepatic tumor progression. A decrease in urinary excretion of 5-hydroxyindoleacetic acid by more than 50% lasting 2-11 months (median, 4) was observed in 5 patients. Four patients were completely or partially relieved of flushing, diarrhea, obstruction or abdominal pain. The side-effects were negligible with the exception of mild fever, headache and confusion only during the first days of therapy. Treatment with IFN alfa-2b offers good palliation to patients with disseminated ileal or caecal carcinoid tumor and carcinoid syndrome.
7例进展期回肠或盲肠类癌肿瘤伴肝转移患者接受了人重组α干扰素（IFNα-2b）治疗，剂量为每日或隔日皮下注射2 - 4×10⁶单位。6例患者有类癌综合征症状。6例患者在4至40多个月（中位数为18个月）期间肿瘤大小无变化，1例患者肝肿瘤进展。5例患者尿中5-羟吲哚乙酸排泄量减少超过50%，持续2至11个月（中位数为4个月）。4例患者的潮红、腹泻、梗阻或腹痛完全或部分缓解。除治疗开始的头几天有轻度发热、头痛和意识模糊外，副作用可忽略不计。IFNα-2b治疗可为播散性回肠或盲肠类癌肿瘤及类癌综合征患者提供良好的姑息治疗。
